These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27858912)

  • 21. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens].
    Kravchenko AV
    Ter Arkh; 2013; 85(11):125-9. PubMed ID: 24432612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
    Reuter S; Braken P; Jensen B; Sierra-Aragon S; Oette M; Balduin M; Kaiser R; Häussinger D
    Eur J Med Res; 2010 Jun; 15(6):231-7. PubMed ID: 20696631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
    Shikuma CM; Wojna V; De Gruttola V; Siriwardhana C; Souza SA; Rodriguez-Benitez RJ; Turner EH; Kallianpur K; Bolzenius J; Chow D; Matos M; Shiramizu B; Clements DM; Premeaux TA; Ndhlovu LC; Paul R
    AIDS; 2023 Nov; 37(13):1987-1995. PubMed ID: 37418541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
    Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
    Xu GG; Guo J; Wu Y
    Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
    Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S;
    HIV Med; 2018 Jan; 19(1):65-71. PubMed ID: 28703491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
    Blanco JR; Arroyo-Manzano D; Rojas-Liévano JF; Crespo M; Bravo I; Pasquau J; Garcia Del Toro M; Herrero C; Rivero A; Moreno S; Llibre JM
    AIDS Res Hum Retroviruses; 2015 Sep; 31(9):893-7. PubMed ID: 26059859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Frequencies and Activation of Regulatory T Cells After the Treatment of HIV-1-Infected Individuals with the CCR5 Antagonist Maraviroc Are Associated with a Reduction in Viral Loads Rather Than a Direct Effect of the Drug on Regulatory T Cells.
    Joedicke JJ; Dirks M; Esser S; Verheyen J; Dittmer U
    Viral Immunol; 2016 Apr; 29(3):192-6. PubMed ID: 27035639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
    Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
    Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
    Kawana-Tachikawa A; Llibre JM; Bravo I; Escrig R; Mothe B; Puig J; Puertas MC; Martinez-Picado J; Blanco J; Manzardo C; Miro JM; Iwamoto A; Pozniak AL; Gatell JM; Clotet B; Brander C;
    PLoS One; 2014; 9(1):e87334. PubMed ID: 24475275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.